



# SEMPERIT GROUP Q1-3 2022 INVESTOR PRESENTATION

**Karl Haider, CEO**

**Helmut Sorger, CFO**

**Kristian Brok, COO**

16 November 2022



# Agenda

Key Highlights (p.2)

Operational Performance (p.4)

Financial Performance & Strategy (p.12)

Outlook (p.22)

Appendix (p.25)



# Operational highlights Q1-3 2022



**Top-line growth in all four Industrial segments offset by steep decline in Medical**



**Industrial Sector with strong comparables despite first signs of economic downturn (weakening order intake, cost inflation)**



**Prices in Medical Sector decline further due to excess inventory additionally limiting demand, resulting in an impairment of EUR 52m**



**Availability and costs of materials gradually easing, supported by proactive management initiatives; similarly, energy supply for winter 2022/23 is ensured**



**Strategy update: major organic growth investment of EUR 110m into Semperflex; resumption of Sempermed separation process following the end of the special cycle with strong EBITDA contribution ('20-'21: EUR 452m)**





# Agenda

Key Highlights (p.2)

Operational Performance (p.4)

Financial Performance & Strategy (p.12)


Outlook (p.22)

Appendix (p.25)




# Strong Industrial Sector performance

### Revenues in EUR m Q1-3'19 – Q1-3'22



### Quarterly development of EBITDA (EURm) and EBITDA margin (%)




- Positive performance driven by high demand and price increases at Semperflex combined with late-cycle upswing at Sempertrans
- Cost inflation and higher energy prices increase margin pressure – sensible price management remains key
- Change in demand as first signs of economic downturn combines with customers actively managing their working capital due to high inventory levels




# Semperflex Q1-3 2022

High performance level during the first nine months

Semperflex



## Q1-3 2022 vs. Q1-3 2021



- Sales up by 47% and EBITDA by 83% yoy on the back of price increases, higher volumes and efficiency gains
- Market and technological leadership resulted in exceptional margins supported by continuing high demand and increased price levels
- Q3'22 beyond peak level as customers' high inventory lowered demand and previous cost pressure started to ease








# Sempertrans Q1-3 2022

Strong operating performance on the back of late-cycle tailwinds, notably in the mining industry

## Sempertrans



### Q1-3 2022 vs. Q1-3 2021



- Higher commodity prices continuously support top-line growth and operating results
- Order book remains at the highest level in more than three years
- Improved overall top line and profitability, margin development supported by selective sales price increases and efficient operating performance



<sup>1</sup> Q1'19 EBITDA: positive effect of EUR 1.3m profit from sale of assets of closed factory in China

<sup>2</sup> Q3'21 EBITDA: positive effect of EUR 3.7m from recycling of foreign exchange differences








# Sempersal Q1-3 2022

Stronger signs of economic downturn due to weak construction industry


Sempersal



## Q1-3 2022 vs. Q1-3 2021



- Weaker order intake compared to peak levels of H1'22
- Top-line growth due to proactive pricing policy
- Margins under pressure due to lower volumes on the back of weaker construction industry, discontinuation of Russian sales activities and customers reducing excess inventory levels
- USA: start of second line of production in early Q3'22










# Semperform Q1-3 2022

Results driven by cyclicalty and product mix

Semperform



## Q1-3 2022 vs. Q1-3 2021



- Continuing strong order intake supported by recovery of skiing industry
- BU Special Application outstanding due to post-pandemic pent-up demand while both BU Handrails and BU Engineered Solutions with mixed results
- Margins remained largely stable as higher prices offset cost inflation with no signs of decreasing order intake so far







# Medical Sector / Sempermed segment Q1-3 2022

Weak volumes and prices back to pre-corona level

Sempermed



## Q1-3 2022 vs. Q1-3 2021



- Excess inventory and low utilisation impact entire industry
- Sales volumes declining and compare with lower level at Q3'21 given production stop in July 2021
- Margins under pressure due to low utilisation, cost inflation and provisions (e.g. gas contracts, inventory)
- Impairment of EUR 51.8m due to changed market dynamics




<sup>1</sup> Q3'19 EBITDA adjusted for EUR 4m due to the positive effect from the release of provision in Sempermed for Brazilian court case for tax liabilities



# Medical Sector – Next steps towards separation

EBITDA development (EUR m)



- Sharp sales price decline for protective gloves brought special cycle to abrupt end
- Low demand due to overstocked markets
- Higher inflation led to cost pressure aggravated by provisions (EUR 11m e.g. gas contracts, inventory)

- EBIT further affected by impairment of EUR 51.8m

- Separation of Medical Sector announced in line with the Industrial Rubber strategy as previously announced in January 2020
- After the end of the pandemic-related special cycle and the now given market dynamics, the separation from the Medical Sector has again moved to the forefront since the summer of 2022
- The Executive Board is decisively taking the next steps towards separation and has started initial talks with potentially interested parties
- The separation from the Sempermed segment shall take place in a timely manner



# Agenda

Key Highlights (p.2)

Operational Performance (p.4)

Financial Performance & Strategy (p.12)

Outlook (p.22)

Appendix (p.25)



# Key CFO Agenda Items

**Special attention to managing the economic downturn**

**Proactive working capital management at structurally higher level going forward**

**&**

**Disciplined cash management and efficient capital allocation**


**Strict cost control to further enhance efficiency**

**Investments in digitalisation and new technologies**





# Revenue development




% change of each segment / sector refers to 2022 vs. 2021.



# Strong performance in Industrial against steep decline in Medical

in EUR m



EBITDA  
Q1-3 2021

324.3

37.4

6.5

10.7

9.9

277.4

-17.7

EBITDA  
Q1-3 2022

68.3

10.3

9.5

12.3

-4.0

-10.5

85.9

EBITDA margin  
Q1-3 2022

27.1%

9.4%

8.3%

14.9%

-1.5%


–

10.3%





# Major drivers of operating performance



in EUR million




# Overview of key financial KPIs, Q1-3 2019 – Q1-3 2022

	Q1-3 2019	Q1-3 2020	Q1-3 2021	Q1-3 2022	Δ 19 vs. 22
<b>EBITDA</b> , in EUR m	60.4	118.5	324.3	85.9	↗ 42.2%
<b>EBITDA margin</b> , in %	9.3	18.0	35.0	10.3	↗ 1.0PP
<b>EBIT</b> , in EUR m	-13.7	159.5	290.0	-9.0	↗ 34.3%
<b>EBIT margin</b> , in %	-2.1	24.3	31.3	-1.1	↗ 1.0PP
<b>Earnings after tax</b> , in EUR m	-34.1	137.3	224.1	-34.6	↘ -1.4%
<b>Free Cashflow</b> , in EUR m	60.2	98.8	160.1	-19.6	↘ n.m.
<b>CAPEX</b> , in EUR m	25.1	17.4	31.2	41.8	↗ 66.5%



# Free cash flow development

- Operating cash flow significantly reduced after steep decline in Medical Sector
- Pre-tax operating cash flow impacted by continuing inventory build-up
- Growing Capex resulted in higher investment cash flow



- Pre-tax operating cash flow (operating cash flow and tax payment in total)
- Investment cash flow
- Free cash flow (adjusted)

Free cash flow adjusted:

Operating cash flow adjusted for tax payments (Q1-3 2020: EUR 10.9m; Q1-3 2021: EUR 24.8m, Q1-3 2022: EUR 49.4m)

Investment cash flow Q1-3 2021 adjusted for investments in USD time deposits (€ -48m) included in investment cash flow (in total € -80m)




# Quarterly CAPEX development 2021-2022

- Industrial continues to receive higher Capex, notably Semperflex and Semperseal
- Stable maintenance Capex for Sempermed being in the process of separation
- FY2022 Capex will exceed prior-year level

## CAPEX per segment

in EUR m






# Working Capital overview

## Components of Working Capital

in EUR m




<sup>1</sup> Trade Working Capital in % of LTM revenues



# Balance sheet structure and financial profile

## Balance sheet structure

Balance sheet 30/09/2022: EUR 841m  
Balance sheet 31/12/2021: EUR 959m



## Financial profile as of 30 September 2022

- **Cash and cash equivalents** at EUR 144m – strong buffer to weather economic headwinds and keep M&A optionality
- **Available credit facilities** total EUR 90m
- **Corporate Schuldschein loan** at EUR 52m
- **“Net debt” remains net cash** at EUR 92m, Net debt / EBITDA below zero (YE’21: below zero)
- **Equity ratio** of 58.6% (YE’21: 56.3%)
- **Dividend** of EUR 1.50 for 2021 paid in May 2022



# Agenda

Key Highlights (p.2)

Operational Performance (p.4)

Financial Performance & Strategy (p.12)

Outlook (p.22)

Appendix (p.25)





# Management agenda



Status Quo  
Q1-3'22

**Strong results in Industrial Sector  
against the backdrop of:**

likely  
deteriorations

**Economic downturn  
and consumer  
sentiment**

**Seasonality**

**Sempermed impacted by  
changed market dynamics**

**Geopolitical crises**

**Potential supply  
constraints and reduced  
components availability**

**Energy crisis in Europe,  
cost inflation, FX,  
working capital**

## Expectations for 2022

**Market dynamics expected to change – with cost inflation being entrenched at a high level throughout the industry and growth slowing down further**

**Outlook confirmed as published in March**

## Expectations for 2023

**Economic downturn will impact the Industrial Sector – resumption of Sempermed separation  
Further pursuing M&A aspirations with more attractive strategic optionality**



# Contact and financial calendar

## Investor Relations Semperit

**Judit Helenyi**, Director Investor Relations

+43 1 79777 - 310

[www.semperitgroup.com/en/ir](http://www.semperitgroup.com/en/ir)

Am Belvedere 10  
1100 Vienna, Austria

## Financial Calendar 2022 / 2023

16.11.2022	Report on Q1-3 2022
22.03.2023	Publication of 2022 annual financial statements
25.04.2023	Annual General Meeting, Vienna
10.05.2023	Report on Q1 2023
10.08.2023	Half-year financial report 2023
08.11.2023	Report on Q1-3 2023

### Disclaimer

The information provided in this presentation does not constitute an offer for the sale of securities nor an invitation to submit an offer to purchase shares of Semperit AG Holding, but exclusively serves information purposes.

The terms “Semperit” or “Semperit Group” in this presentation refer to the group; “Semperit AG Holding” or “Semperit Aktiengesellschaft Holding” is used to refer to the parent company (individual company).

We have prepared this presentation and verified the information it contains with the greatest possible care. Nevertheless, rounding, typesetting and printing errors cannot be ruled out. Rounding of differences in the summation rounded amounts and percentages may arise from the automatic processing of data.

The forecasts, plans and forward-looking statements contained in this presentation are based on the knowledge and information available and the assessments made at the time that this presentation was prepared. As is true of all forward-looking statements, these statements are subject to risk and uncertainties. As a result, actual events may deviate significantly from these expectations. No liability whatsoever is assumed for the accuracy of projections or for the achievement of planned targets or for any other forward-looking statements. Words such as “expect,” “want”, “believe,” “anticipate,” “includes,” “plan,” “assumes,” “estimate,” “projects,” “intends,” “should,” “will,” “shall,” or variations of such words are generally part of forward-looking statements.

Furthermore, there is no guarantee that the contents are complete. Statements referring to people are valid for both men and women.



# Agenda

Key Highlights (p.2)

Operational Performance (p.4)

Financial Performance & Strategy (p.12)

Outlook (p.22)

Appendix (p.25)



# Sectors and Group: Q1-3 2022 vs Q1-3 2021

in EUR m	Industrial Sector			Medical Sector			Semperit Group		
	Q1-3 2022 <sup>1</sup>	Q1-3 2021	%	Q1-3 2022	Q1-3 2021	%	Q1-3 2022 <sup>1</sup>	Q1-3 2021	%
<b>Revenue</b>	<b>558.4</b>	409.4	+36.4%	<b>271.2</b>	516.7	-47.5%	<b>829.6</b>	926.1	-10.4%
<b>EBITDA</b>	<b>100.4</b>	64.5	+55.6%	<b>-4.0</b>	277.4	n.a.	<b>85.9</b>	324.3	-73.5%
EBITDA margin	<b>18.0%</b>	15.8%	+2.2 PP	<b>-1.5%</b>	53.7%	-55.2 PP	<b>10.3%</b>	35.0%	-24.7 PP
<b>EBIT</b>	<b>78.1</b>	46.0	+69.7%	<b>-75.6</b>	262.6	n.a.	<b>-9.0</b>	290.0	n.a.
EBIT margin	<b>14.0%</b>	11.2%	+2.7 PP	<b>-27.9%</b>	50.8%	-78.7 PP	<b>-1.1%</b>	31.3%	-32.4 PP
<b>Adj. EBIT</b>	<b>80.2</b>	46.0	+74.3%	<b>-23.8</b>	262.6	n.a.	<b>44.9</b>	290.0	-84.5%
Adj. EBIT margin	<b>14.4%</b>	11.2%	+3.1 PP	<b>-8.8%</b>	50.8%	-59.6 PP	<b>5.4%</b>	31.3%	-25.9 PP
<b>Earnings after tax</b>	<b>-</b>	-	-	<b>-</b>	-	-	<b>-34.6</b>	224.1	n.a.
<b>Earnings per share in EUR</b>	<b>-</b>	-	-	<b>-</b>	-	-	<b>-1.7</b>	10.8	n.a.
<b>Additions in tangible and intangible assets</b>	<b>17.3</b>	17.2	+1.0%	<b>12.9</b>	15.0	-14.0%	<b>32.4</b>	33.1	-1.9%
<b>Employees</b>	<b>3,874</b>	3,720	+4.2%	<b>2,716</b>	3,170	-14.3%	<b>6,700</b>	7,027	-4.7%

<sup>1</sup> Adjusted for the negative one-off effect of the impairments in the segments Sempermed and Semperseal (Q1-3 2022 and Q3 2022: EBIT effect EUR -53.9 million, earnings after tax EUR -53.9 million).

Figures of Semperit Group also contain intercompany consolidation and the results of the Corporate Segment




# Semperit Group adj. where applicable


## Semperit Group adj. where applicable

in EUR m	FY 2019	Q1 2020	Q2 2020 adj. <sup>1)</sup>	Q3 2020 adj. <sup>2)</sup>	Q4 2020 adj.	FY 2020 adj. <sup>3)</sup>	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021	Q1 2022	Q2 2022	Q3 2022 adj. <sup>4)</sup>
<b>Revenue</b>	<b>840.6</b>	199.1	219.8	238.2	270.5	<b>927.6</b>	323.1	337.7	265.3	256.1	<b>1,182.2</b>	277.0	293.6	<b>259.0</b>
<b>EBITDA</b>	<b>63.8</b>	16.9	40.7	60.9	90.0	<b>208.6</b>	122.2	125.3	76.8	37.5	<b>361.8</b>	36.5	38.7	<b>10.7</b>
EBITDA margin	<b>7.6%</b>	8.5%	18.5%	25.6%	33.3%	<b>22.5%</b>	37.8%	37.1%	28.9%	14.6%	<b>30.6%</b>	13.2%	13.2%	<b>4.1%</b>
<b>EBIT</b>	<b>28.2</b>	9.8	33.6	49.2	78.8	<b>171.4</b>	110.8	113.8	65.4	25.0	<b>315.0</b>	23.7	24.7	<b>-3.5</b>
EBIT margin	<b>3.4%</b>	4.9%	15.3%	20.7%	29.1%	<b>18.5%</b>	34.3%	33.7%	24.7%	9.8%	<b>26.6%</b>	8.6%	8.4%	<b>-1.4%</b>

EBITDA adj. per quarter



EBIT adj. per quarter



<sup>1)</sup> Q2 2020: adjusted for the positive one-off effect from the write-up in the Sempermed segment (EBIT: EUR 88.8 million) and the negative one-off effect from the impairment in the Sempertrans segment (EBIT effect –20.0 Million EUR) <sup>2)</sup> Q3 2020: adjusted for the special effect from the write-up in the Sempermed segment (EBIT: EUR –2.1 million) and the special effect from the impairment in the Sempertrans segment (EBIT effect EUR +0.1 million). <sup>3)</sup> 2020 adjusted for the positive one-off effect from the reversal of impairment in the Sempermed segment (EBIT effect: +86.2 million EUR) and for the negative one-off effect of the impairment in the Sempertrans segment (EBIT effect EUR –19.8 million) <sup>4)</sup> Q3 2022: adjusted for the negative one-off effect of the impairments in segments Sempermed and Semperseal (Q3 2022: EBIT effect EUR -53.9 million, earnings after tax EUR -53.9 million).



# Semperflex and Sempertrans (adj. where applicable)

## Semperflex (Hoses)

	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	FY 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021	Q1 2022	Q2 2022	Q3 2022
in EUR m																		
<b>Revenue</b>	61.1	59.7	53.8	48.0	<b>222.7</b>	46.8	51.5	46.6	45.0	<b>189.9</b>	54.7	59.7	57.7	68.4	<b>240.5</b>	79.8	93.9	<b>78.5</b>
<b>EBITDA</b>	13.9	14.5	10.8	8.7	<b>47.9</b>	9.3	14.0	11.4	7.2	<b>41.9</b>	12.3	13.9	11.2	13.9	<b>51.3</b>	19.6	27.3	<b>21.5</b>
EBITDA margin	22.8%	24.3%	20.1%	18.1%	<b>21.5%</b>	19.9%	27.2%	24.5%	16.0%	<b>22.1%</b>	22.5%	23.3%	19.3%	20.4%	<b>21.3%</b>	24.5%	29.0%	<b>27.3%</b>
<b>EBIT</b>	11.1	11.5	7.7	5.7	<b>36.0</b>	6.5	11.2	8.7	4.5	<b>30.9</b>	9.6	11.1	8.4	11.0	<b>40.0</b>	16.6	24.3	<b>18.5</b>
EBIT margin	18.2%	19.2%	14.3%	11.9%	<b>16.2%</b>	13.9%	21.8%	18.6%	10.0%	<b>16.3%</b>	17.5%	18.5%	14.5%	16.1%	<b>16.6%</b>	20.8%	25.8%	<b>23.6%</b>

## Sempertrans (Conveyor belts)

	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020 adj. <sup>1)</sup>	Q3 2020 adj. <sup>2)</sup>	Q4 2020 <sup>3)</sup>	FY 2020 adj. <sup>4)</sup>	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021	Q1 2022	Q2 2022	Q3 2022
in EUR m																		
<b>Revenue</b>	30.4	37.8	35.1	30.6	<b>134.0</b>	29.5	32.5	28.4	22.7	<b>113.1</b>	26.9	24.2	28.0	25.3	<b>104.5</b>	28.3	41.5	<b>40.0</b>
<b>EBITDA</b>	2.7	5.4	4.6	0.8	<b>13.5</b>	1.6	5.0	2.1	0.0	<b>8.7</b>	1.0	0.8	4.7	0.4	<b>6.8</b>	1.3	5.3	<b>3.7</b>
EBITDA margin	9.0%	14.2%	13.1%	2.5%	<b>10.1%</b>	5.4%	15.4%	7.6%	0.0%	<b>7.7%</b>	3.8%	3.3%	16.7%	1.4%	<b>6.6%</b>	4.5%	12.9%	<b>9.2%</b>
<b>EBIT</b>	1.8	3.8	3.6	-0.3	<b>8.9</b>	0.6	3.9	1.4	-0.6	<b>4.9</b>	0.2	-0.1	3.8	-0.7	<b>3.2</b>	0.3	4.4	<b>2.6</b>
EBIT margin	6.0%	10.0%	10.4%	-0.9%	<b>6.7%</b>	1.9%	11.9%	5.0%	-2.6%	<b>4.3%</b>	0.7%	-0.2%	13.6%	-2.9%	<b>3.1%</b>	1.2%	10.5%	<b>6.5%</b>

<sup>1)</sup> Q2 2020: adjusted for the negative one-off effect from the impairment in the Sempertrans segment (EBIT effect: EUR 20.0 million).

<sup>2)</sup> Q3 2020: adjusted for the special effect of the impairment in the Sempertrans segment (EBIT effect: EUR +0.1 million)

<sup>3)</sup> Q4 2020: adjusted for the special effect of the impairment in the Sempertrans segment (EBIT effect: EUR +0.1 million)

<sup>4)</sup> 2020: Adjusted for the negative one-off effect of the impairment in the Sempertrans segment (2020 EBIT effect: EUR 19.8 million)



# Semperform and Semperseal (adj. where applicable)

## Semperform (Window and door profiles, Handrails) - before 2020

	FY 2017 adj.	Q1 2018	Q2 2018	Q3 2018	FY 2018	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019
in EUR m										
<b>Revenue</b>	<b>185.0</b>	47.5	50.7	50.3	<b>192.2</b>	49.9	50.5	47.8	42.4	<b>190.6</b>
<b>EBITDA</b>	<b>21.5</b>	4.5	7.3	6.2	<b>21.9</b>	7.9	8.3	6.6	3.3	<b>26.0</b>
EBITDA margin	<b>11.6%</b>	9.6%	14.4%	12.2%	<b>11.4%</b>	15.7%	16.4%	13.8%	7.8%	<b>13.6%</b>
<b>EBIT</b>	<b>13.3</b>	2.4	5.1	4.2	<b>13.2</b>	5.4	5.9	4.2	0.5	<b>16.0</b>
EBIT margin	<b>7.2%</b>	5.0%	10.1%	8.4%	<b>6.9%</b>	10.9%	11.6%	8.7%	1.1%	<b>8.4%</b>

## Semperform (Window and door profiles, Handrails) - after 2020

	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	FY 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021	Q1 2022	Q2 2022	Q3 2022
in EUR m																		
<b>Revenue</b>	22.4	24.6	22.3	21.8	91.1	19.9	21.9	20.4	19.6	<b>81.8</b>	19.8	23.6	23.3	23.9	<b>90.6</b>	26.2	27.5	<b>29.3</b>
<b>EBITDA</b>	4.0	4.8	4.1	2.7	15.6	3.5	5.0	4.0	2.5	<b>15.0</b>	3.1	3.6	3.3	2.5	<b>12.4</b>	3.2	5.0	<b>4.1</b>
EBITDA margin	17.7%	19.6%	18.4%	12.2%	17.1%	17.5%	22.6%	19.6%	12.9%	<b>18.3%</b>	15.4%	15.2%	14.1%	10.3%	<b>13.7%</b>	12.2%	18.3%	<b>13.9%</b>
<b>EBIT</b>	3.1	4.0	3.2	1.7	12.0	2.6	4.1	3.1	1.6	<b>11.3</b>	2.1	2.6	2.3	1.4	<b>8.5</b>	2.1	4.0	<b>3.0</b>
EBIT margin	13.9%	16.1%	14.3%	7.7%	13.1%	12.9%	18.5%	15.1%	8.0%	<b>13.8%</b>	10.8%	11.2%	10.0%	6.0%	<b>9.4%</b>	8.2%	14.4%	<b>10.3%</b>

## Sempersal (Profiles and Rubber Sheeting) starting in 2020

	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	FY 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021	Q1 2022	Q2 2022	Q3 2022 adj. <sup>1)</sup>
in EUR m																		
<b>Revenue</b>	27.5	25.8	25.6	20.5	99.5	25.4	21.7	24.4	22.2	<b>93.6</b>	28.7	30.3	32.4	29.1	<b>120.5</b>	36.6	38.4	<b>38.3</b>
<b>EBITDA</b>	3.9	3.4	2.5	0.6	10.4	3.3	3.2	2.9	1.7	<b>11.0</b>	4.2	2.4	4.1	0.9	<b>11.6</b>	2.4	3.9	<b>3.2</b>
EBITDA margin	14.1%	13.2%	9.8%	3.0%	10.5%	12.8%	14.7%	12.0%	7.5%	<b>11.8%</b>	14.7%	7.9%	12.6%	3.0%	<b>9.6%</b>	6.5%	10.1%	<b>8.3%</b>
<b>EBIT</b>	2.3	1.9	1.0	-1.2	4.0	1.8	1.7	1.4	0.2	<b>5.1</b>	2.6	0.8	2.5	-0.9	<b>5.1</b>	0.5	2.3	<b>-0.6</b>
EBIT margin	8.4%	7.3%	3.9%	-5.8%	4.0%	6.9%	8.0%	5.8%	1.1%	<b>5.5%</b>	9.2%	2.6%	7.7%	-3.1%	<b>4.2%</b>	1.4%	5.9%	<b>-1.4%</b>

<sup>1)</sup> Adjusted for the negative one-off effect of the impairment in the segment Semperseal (Q3 2022: EBIT effect: EUR -2,1 million).

Split of former Semperform into Semperseal and Semperform as of 1<sup>st</sup> January 2020 – historic Semperform numbers for 2019 adapted for this split accordingly





# Sempermed (adj. where applicable)

Sempermed (Gloves)																		
in EUR m	Q1 2019	Q2 2019	Q3 2019 adj. <sup>1)</sup>	Q4 2019	FY 2019 <sup>2)</sup>	Q1 2020	Q2 2020 adj. <sup>3)</sup>	Q3 2020 adj. <sup>4)</sup>	Q4 2020 <sup>5)</sup>	FY 2020 adj. <sup>6)</sup>	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021	Q1 2022	Q2 2022	Q3 2022 adj. <sup>7)</sup>
<b>Revenue</b>	71.5	76.4	78.2	67.3	<b>293.3</b>	77.5	92.2	118.4	161.1	<b>449.2</b>	192.9	199.8	124.0	109.4	<b>626.1</b>	106.1	92.3	<b>72.9</b>
<b>EBITDA</b>	-0.9	0.6	1.8	-0.1	<b>1.4</b>	4.8	18.2	44.4	83.0	<b>150.4</b>	105.3	115.3	56.9	23.7	<b>301.1</b>	13.3	2.3	<b>-19.6</b>
EBITDA margin	-1.2%	0.8%	2.3%	-0.1%	<b>0.5%</b>	6.1%	19.7%	37.5%	51.5%	<b>33.5%</b>	54.6%	57.7%	45.9%	21.7%	<b>48.1%</b>	12.6%	2.5%	<b>-26.9%</b>
<b>EBIT</b>	-2.8	-1.4	-0.3	-0.9	<b>-5.5</b>	4.4	17.6	38.9	77.8	<b>138.7</b>	100.2	110.3	52.1	18.3	<b>280.9</b>	7.6	-4.7	<b>-78.5</b>
EBIT margin	-3.9%	-1.9%	-0.4%	-1.4%	<b>-1.9%</b>	5.5%	19.1%	32.8%	48.3%	<b>30.9%</b>	52.0%	55.2%	42.0%	16.7%	<b>44.9%</b>	7.2%	-5.1%	<b>-107.6%</b>

<sup>1)</sup> Q3 2019 adjusted for negative one-off effect of EUR 46.8 million from impairment of Sempermed (adj. for EBIT) and EUR 4 million (EBITDA, EBIT) due to release of provision in Sempermed for Brazilian court case for tax liabilities.

<sup>2)</sup> 2019: adjusted for the positive one-off effect from the reversal of a provision for the tax procedure on levies in Brazil (EBITDA, EBIT: EUR 4.0 million), as well as the negative effect of the impairments for the Sempermed segment (EBIT: -48.8 million EUR)

<sup>3)</sup> Q2 2020: adjusted for the positive one-off effect from the reversal of impairment in the Sempermed segment (EBIT: EUR +88.8 million)

<sup>4)</sup> Q3 2020: adjusted for the special effect of the write-up in the Sempermed segment (EBIT effect: EUR -2.1 million)

<sup>5)</sup> Q4 2020: adjusted for the special effect of the write-up in the Sempermed segment (EBIT effect: EUR -0.5 million)

<sup>6)</sup> 2020: adjusted for the positive one-off effect of the reversal of impairment in the Sempermed segment (2020 EBIT effect: EUR +86.2 million)

<sup>7)</sup> Q3 2022: adjusted for the negative one-off effect of the impairment in the segment Sempermed (Q3 2022: EBIT effect: EUR -51,8 million).



# Key figures 2011-2021

Key performance figures											
in EUR m	2011 <sup>1)</sup>	2012	2013	2014 <sup>3)</sup>	2015 <sup>3)</sup>	2016 adj. <sup>4)</sup>	2017 adj. <sup>5)</sup>	2018 adj. <sup>6)</sup>	2019 adj. <sup>7)</sup>	2020 adj. <sup>8)</sup>	2021
Revenue	820.0	828.6	906.3	858.3	914.7	852.4	874.2	878.5	840.6	927.6	1,182.2
<b>EBITDA</b>	110.0	108.7	132.5	101.9	96.2	74.7	35.8	50.3	63.8	208.6	361.8
EBITDA margin	13.4%	13.1%	14.6%	11.9%	10.5%	8.8%	4.1%	5.7%	7.6%	22.5%	30.6%
<b>EBIT</b>	80.4	72.5	87.8	63.8	66.7	41.1	-0.8	15.4	28.2	171.4	315.0
EBIT margin	9.8%	8.8%	9.7%	7.4%	7.3%	4.8%	-0.1%	1.7%	3.6%	18.5%	26.6%
<b>Earnings after tax</b>	51.8	46.2	54.9	37.8	46.4	15.2	-43.9	-17.3	-0.2	121.9	247.5
<b>EPS<sup>2)</sup>, in EUR</b>	2.52	2.25	2.65	1.85	2.26	0.74	-2.08	-1.06	-0.33	5.53	11.99
<b>Gross cash flow</b>	89.4	85.6	116.2	89.9	55.7	48.1	32.2	37.4	46.70	193.7	323.4
<b>Return on equity</b>	13.6%	11.4%	13.3%	8.6%	12.8%	4.6%	-15.8%	-4.2%	-16.3%	58.0%	45.7%


Balance sheet key figures											
in EUR m	2011 <sup>1)</sup>	2012	2013	2014 <sup>3)</sup>	2015 <sup>3)</sup>	2016	2017	2018	2019	2020	2021
<b>Balance sheet total</b>	616.7	824.5	852.1	826.3	937.8	1034.5	853.2	768.8	701.8	764.4	958.6
<b>Equity<sup>2)</sup></b>	379.4	406.2	411.5	443.8	363.3	329.3	278.5	329.5	237.4	332.3	540.1
<b>Equity ratio</b>	61.5%	49.3%	48.3%	53.7%	38.7%	31.8%	32.6%	42.9%	39.0%	43.5%	56.3%
<b>Investments in tangible and intangible assets</b>	45.1	41.2	49.7	67.4	71.8	65.1	74.5	80.8	31.9	26.4	47.9
<b>Employees, at balance sheet date, FTEs</b>	8,025	9,577	10,276	6,888	7,053	6,974	6,838	6,773	6,902	6,943	6,948

<sup>1)</sup> 2011 restated (see Annual Report 2012, Notes 2.18). <sup>2)</sup> 2014 and 2015 restated. <sup>3)</sup> 2016 without profit contribution from SSC / Thai glove JV, impairment Sempermed and trade tax / levies in Brazil. <sup>4)</sup> 2017 adjusted for positive one-off effects from JV transaction of EUR 85m (EUR 65m for net profit) and negative one-off effects from impairment at Sempermed (EUR 26m adj. EBIT, EAT only), from restructuring expenses in France (EUR 11m), valuation adjustment in IT (EUR 4m EBITDA, EUR 3m EBIT) and expenses resulting from tax audit in Austria (EUR 5m, mainly for refund of energy supply charge). <sup>5)</sup> 2018 adjusted for negative one-off effects from closure of Sempertrans site in China (EUR 4m for EBITDA, EUR 8m for EBIT and EAT) and for impairment of Sempermed of EUR 55m (adj. for EBIT and EAT only). <sup>6)</sup> FY 2019 adjusted for positive one-off effects of EUR 4m (EBITDA, EBIT, EAT) due to release of provision in Sempermed for Brazilian court case for tax liabilities and for negative one-off effects of EUR 48.8m from impairment at Sempermed from impairment of Sempermed (adj. for EBIT and EAT). <sup>7)</sup> 2020 adjusted for the positive one-off effect from the reversal of impairment in the Sempermed segment (EBIT effect: +86.2 million EUR; earnings after tax effect: +88.8 million EUR) and for the negative one-off effect of the impairment in the Sempertrans segment (EBIT effect EUR -19.8 million; earnings after taxes effect: EUR -16.1 million)



# Overview price indices Butadiene

## Price movements for raw materials<sup>1)</sup> became highly unpredictable





<sup>1)</sup> Selected raw materials are shown for illustration purposes only. Indices based on 01/01/2019 = 100.0



# Overview price indices LFO-F-NWE / wire rod

## Significant increase for raw material<sup>1)</sup> used in industrial segments



<sup>1)</sup> Selected raw materials are shown for illustration purposes only. Indices based on 01/01/2019 = 100.0



# Product / market position / segment overview, FY 2021

in EUR m

Semperit Group

Group	Industrial Sector				Medical Sector	
	Semperflex	Sempertrans	Semperform	Semperseal	Sempermed	
Revenue	1.182.2	240.5 / 20% <sup>1)</sup>	104.5 / 9% <sup>1)</sup>	90.6 / 8% <sup>1)</sup>	120.5 / 10% <sup>1)</sup>	626.1 / 53% <sup>1)</sup>
EBITDA	361.8 <sup>2)</sup>	51.3	6.8	12.4	11.6	301.1
Employees	6,948 <sup>2)</sup>	1,753 / 25% <sup>3)</sup>	921 / 13% <sup>3)</sup>	576 / 8% <sup>3)</sup>	514 / 7% <sup>3)</sup>	3,038 / 44% <sup>3)</sup>

Products and market position

## Hydraulic hoses

# 3 position globally / leader in hose only



## Industrial hoses

# 2 - 3 position in Europe  
# 6 position globally



## Conveyor belts

One of the leading suppliers of heavy-duty steel cord and textile conveyor belts



## HSA\* / SES\*\*

Leading European manufacturers of moulded and extrusion products made of polymer and plastics (handrails, cable car rings, ski foils and Engineered Solutions)



## Profiles / Rubber Sheeting

Leading European manufacturer of sealing profiles and elastomer sheeting (construction, packaging, machinery, HVAC, marine, electric systems)



## Examination gloves

Among the top 15 glovemakers in the world



## Surgical gloves

Among the leading companies in Europe




\*Handrails, Special Applications  
\*\* Semperit Engineered Solutions

<sup>1)</sup> Revenue in % of Group revenue.  
<sup>2)</sup> Group figure includes corporate center of EUR -21m, 147 employees.  
<sup>3)</sup> Employees in % of Group employees.



# Shareholder Structure

Shareholder structure



- Semperit is listed on the Vienna Stock Exchange since 1890
- Total of 20,573,434 shares
- B & C Holding Österreich GmbH is part of B & C Privatstiftung, an Austrian based private foundation / trust
- Primary focus of B & C is pursuing the foundation's mission to "foster Austrian entrepreneurship"
- Semperit benefits from supportive ownership structure with long-term commitment from B & C